Recently, the State Food and Drug Administration said that a comprehensive domestic and international monitoring and evaluation results, that the use of sibutramine may increase the risk of serious cardiovascular disease, the risk of weight loss treatment outweighs the benefits, decided to stop the production, sale and use of sibutramine preparations and API in China, has been listed by the manufacturer of drugs responsible for the recall and destruction. It is reported that the products called off include Qomei, Ao Qu light, can show, Sysme, Qu Ting, Pu Xiu, Ting Li, Aulina, Qu Jing, new Finmeline, Xi Qing, Shen Zhihua, Heng Yun, Miao Le, Nometing and many other brands of weight loss drugs. The State Drug Administration recommends that people who are either treating obesity or hoping to achieve shape through weight reduction should adhere to a long-term scientific lifestyle to maintain their weight and reduce rebound; it is recommended that patients who are currently using sibutramine should promptly consult their doctors and discuss alternative medications with them.